A platform designed for cell-type-specific delivery of small molecules and biologics, focusing on targeting brain and retinal endothelial cells. This approach aims to treat cerebral cavernous malformations through the conjugation of rapamycin with endothelial-targeting functional groups. The platform holds promise for additional indications, including vascular dementia, multiple sclerosis, and diabetic retinopathy.